Reference profile correlation reveals estrogen-like trancriptional activity of curcumin

Cellular Physiology and Biochemistry

Volumn 26, Issue 3, 2010, Pages 471-482

  Bachmeier, Beatrice E ^a   Mirisola, Valentina ^b   Romeo, Francesco ^b   Generoso, Luca ^c   Esposito, Alessia ^b   Dell'Eva, Raffaella ^b   Blengio, Fabiola ^b   Killian, Peter H ^a   Albini, Adriana ^c   Pfeffer, Ulrich ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF GENOA   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

Breast cancer; Chemoprevention; Gene expression profiling; Phytoestrogen; Reference profile correlation

Indexed keywords

CURCUMIN; ENTEROLACTONE; ESTRADIOL; PHYTOESTROGEN; QUERCETIN;

ARTICLE; BREAST CANCER; CELL LINE; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 78650006975     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320570     Document Type: Article

References (49)

1. McPherson K, Steel CM, Dixon JM: Abc of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000;321:624-628.
2. Coombs NJ, Taylor R, Wilcken N, Boyages J: Hormone replacement therapy and breast cancer: Estimate of risk. BMJ 2005;331:347-349.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard B V, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-333.
4. Mitra AK, Faruque FS, Avis AL: Breast cancer and environmental risks: Where is the link? J Environ Health 2004;66:24-32, 40; quiz 41-22.
5. Rice S, Whitehead SA: Phytoestrogens and breast cancer-promoters or protectors? Endocr Relat Cancer 2006;13:995-1015.
6. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139:4252-4263.
7. Ohno S, Shinoda S, Toyoshima S, Nakazawa H, Makino T, Nakajin S: Effects of flavonoid phytochemicals on cortisol production and on activities of steroidogenic enzymes in human adrenocortical h295r cells. J Steroid Biochem Mol Biol 2002;80:355-363.
8. Svechnikov K, Supornsilchai V, Strand ML, Wahlgren A, Seidlova-Wuttke D, Wuttke W, Soder O: Influence of long-term dietary administration of procymidone, a fungicide with anti-androgenic effects, or the phytoestrogen genistein to rats on the pituitary-gonadal axis and leydig cell steroidogenesis. J Endocrinol 2005;187:117-124.
9. Soto AM, Sonnenschein C, Chung KL, Fernandez MF, Olea N, Serrano FO: The e-screen assay as a tool to identify estrogens: An update on estrogenic environmental pollutants. Environ Health Perspect 1995;103 Suppl 7:113-122.
10. Gutendorf B, Westendorf J: Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. Toxicology 2001;166:79-89.
11. Bouker KB, Hilakivi-Clarke L: Genistein: Does it prevent or promote breast cancer? Environ Health Perspect 2000;108:701-708.
12. Zava DT, Duwe G: Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer 1997;27:31-40.
13. Hsieh CY, Santell RC, Haslam SZ, Helferich WG: Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF7) cells in vitro and in vivo. Cancer Res 1998;58:3833-3838.
14. Le Bail JC, Varnat F, Nicolas JC, Habrioux G: Estrogenic and antiproliferative activities on MCF7 human breast cancer cells by flavonoids. Cancer Lett 1998;130:209-216.
15. Dixon-Shanies D, Shaikh N: Growth inhibition of human breast cancer cells by herbs and phytoestrogens. Oncol Rep 1999;6:1383-1387.
16. Hsu JT, Hung HC, Chen CJ, Hsu WL, Ying C: Effects of the dietary phytoestrogen biochanin a on cell growth in the mammary carcinoma cell line MCF7. J Nutr Biochem 1999;10:510-517.
17. Nakagawa H, Yamamoto D, Kiyozuka Y, Tsuta K, Uemura Y, Hioki K, Tsutsui Y, Tsubura A: Effects of genistein and synergistic action in combination with eicosapentaenoic acid on the growth of breast cancer cell lines. J Cancer Res Clin Oncol 2000;126:448-454.
18. Dampier K, Hudson EA, Howells LM, Manson MM, Walker RA, Gescher A: Differences between human breast cell lines in susceptibility towards growth inhibition by genistein. BrJCancer 2001;85:618-624.
19. De Lemos ML: Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Ann Pharmacother 2001;35:1118-1121.
20. Schmitt E, Dekant W, Stopper H: Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol In Vitro 2001;15:433-439.
21. Wang C, Kurzer MS: Effects of phytoestrogens on DNA synthesis in MCF7 cells in the presence of estradiol or growth factors. Nutr Cancer 1998;31:90-100.
22. Collins-Burow BM, Burow ME, Duong BN, McLachlan JA: Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms. Nutr Cancer 2000;38:229-244.
23. Yin F, Giuliano AE, Law RE, Van Herle AJ: Apigenin inhibits growth and induces g2/m arrest by modulating cyclin-cdk regulators and erk map kinase activation in breast carcinoma cells. Anticancer Res 2001;21:413-420.
24. Wang C, Kurzer MS: Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr Cancer 1997;28:236-247.
25. Saarinen NM, Penttinen PE, Smeds AI, Hurmerinta TT, Makela SI: Structural determinants of plant lignans for growth of mammary tumors and hormonal responses in vivo. J Steroid Biochem Mol Biol 2005;93:209-219.
26. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SAA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML, for the WHII: Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045.
27. Katalinic A, Rawal R: Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008;107:427-430.
28. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC: Multiple biological activities of curcumin: A short review. Life Sci 2006;78:2081-2087.
29. Valsta LM, Kilkkinen A, Mazur W, Nurmi T, Lampi AM, Ovaskainen ML, Korhonen T, Adlercreutz H, Pietinen P: Phyto-oestrogen database of foods and average intake in finland. Br J Nutr 2003;89 Suppl 1:S31-38.
30. Erlund I, Freese R, Marniemi J, Hakala P, Alfthan G: Bioavailability of quercetin from berries and the diet. Nutr Cancer 2006;54:13-17.
31. Shenouda NS, Zhou C, Browning JD, Ansell PJ, Sakla MS, Lubahn DB, Macdonald RS: Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer 2004;49:200-208.
32. Boccardo F, Lunardi G, Guglielmini P, Parodi M, Murialdo R, Schettini G, Rubagotti A: Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. Eur J Cancer 2004;40:84-89.
33. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP: Summaries of affymetrix genechip probe level data. Nucleic Acids Res 2003;31:e15.
34. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J: Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
35. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. ProcNatlAcadSciUSA 2001;98:5116-5121.
36. Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: David: Database for annotation, visualization, and integrated discovery. Genome Biol 2003;4:P3.
37. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative group on hormonal factors in breast cancer. Lancet 1997;350:1047-1059.
38. Carroll JS, Brown M: Estrogen receptor target gene: An evolving concept. Mol Endocrinol 2006;20:1707-1714.
39. Hart LL, Davie JR: The estrogen receptor: More than the average transcription factor. Biochem Cell Biol 2002;80:335-341.
40. O'Lone R, Frith MC, Karlsson EK, Hansen U: Genomic targets of nuclear estrogen receptors. Mol Endocrinol 2004;18:1859-1875.
41. Singh S, Aggarwal BB: Activation of transcription factor nf-kappa b is suppressed by curcumin (diferuloylmethane) [corrected]. JBiolChem 1995;270:24995-25000.
42. Bachmeier B, Nerlich AG, Iancu CM, Cilli M, Schleicher E, Vene R, Dell'Eva R, Jochum M, Albini A, Pfeffer U: The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem 2007;19:137-152.
43. Bachmeier BE, Mohrenz IV, Mirisola V, Schleicher E, Romeo F, Hohneke C, Jochum M, Nerlich AG, Pfeffer U: Curcumin downregulates the inflammatory cytokines cxcl1 and -2 in breast cancer cells via nfkappab. Carcinogenesis 2008;29:779-789.
44. Valentine JE, Kalkhoven E, White R, Hoare S, Parker MG: Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression. J Biol Chem 2000;275:25322-25329.
45. Chu S, Nishi Y, Yanase T, Nawata H, Fuller PJ: Transrepression of estrogen receptor beta signaling by nuclear factor-kappab in ovarian granulosa cells. Mol Endocrinol 2004;18:1919-1928.
46. Kumar V, Chambon P: The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 1988;55:145-156.
47. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL: The structural basis of estrogen receptor/ coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-937.
48. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker M G, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826.
49. Mirisola V, Zuccarino A, Bachmeier BE, Sormani MP, Falter J, Nerlich A, Pfeffer U: Cxcl12/sdf1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival. Eur J Cancer 2009;45:2579-2587.